Clinical utility of serum type III collagen in patients with pancreatic carcinoma

I Chen; N Willumsen; C Dehlendorff; A Johansen; B V Vittrup; M Krüger; P Pfeiffer; J K Bjerregaard; S E Bojesen; S E Nielsen; N H Holländer; M K Yilmaz; L S Rasmussen; M Karsdal; J S Johansen

doi:10.1093/annonc/mdy282.135

Clinical utility of serum type III collagen in patients with pancreatic carcinoma

I Chen, N Willumsen, C Dehlendorff, A Johansen, B V Vittrup, M Krüger, P Pfeiffer, J K Bjerregaard, S E Bojesen, S E Nielsen, N H Holländer, M K Yilmaz, L S Rasmussen, M Karsdal, J S Johansen

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

13 Citationer (Scopus)

Abstract

Background: Collagen is highly expressed in pancreatic cancer (PC) stroma. Collagen accumulation compromises penetration of macromolecules into tumor tissues and is associated with poorer outcome and increased tumor invasion. The aim of this biomarker study was to investigate the clinical utility of serum pro-peptide of type III collagen (PRO-C3) in patients (pts) with PC.Methods: A cohort from the Danish BIOPAC study (ClinicalTrials.gov ID: NCT03311776) including 851 consecutive subjects with histologically confirmed PC, ampullary carcinoma (n = 45), distal biliary tract cancer (n = 32) and benign lesions (n = 88) were enrolled. Serum PRO-C3 was determined by ELISA (Nordic Bioscience, PRO-C3 protocol). The main outcome was survival among pts with PC (male/female: 458/393; age \lt;50 vs. 50-69 vs. ≥70: 41/477/333; ECOG Performance Status (PS) of 0/1/2+: 315/340/110; stage 1 + 2/3/4: 234/142/456; diabetes yes/no: 207/629; smoking yes/no: 508/265; alcohol yes/no: 183/588; body mass index: low/normal/overweight: 62/426/254; Charlson Age-Comorbidity index (CACI) 0/1-2/3+: 34/296/504) in relation to PRO-C3 levels. Serum CA19-9, hyaluronic acid (HA), C-reactive protein (CRP), interleukin-6 (IL-6) and YKL-40 were measured. Hazard ratios (HRs) and 95\% confidence intervals (CIs) were estimated by Cox proportional hazards regression.

Originalsprog	Engelsk
Artikelnummer	752P
Tidsskrift	Annals of Oncology
Vol/bind	29
Udgave nummer	Suppl. 8
Sider (fra-til)	viii257
Antal sider	1
ISSN	0923-7534
DOI	https://doi.org/10.1093/annonc/mdy282.135
Status	Udgivet - okt. 2018
Begivenhed	ESMO 2018 Congress (European Society for Medical Oncology): Securing access to optimal cancer care - München, Tyskland Varighed: 19 okt. 2018 → 23 okt. 2018 http://www.esmo.org/Conferences/ESMO-2018-Congress

Konference

Konference	ESMO 2018 Congress (European Society for Medical Oncology)
Land/Område	Tyskland
By	München
Periode	19/10/2018 → 23/10/2018
Internetadresse	http://www.esmo.org/Conferences/ESMO-2018-Congress

Adgang til dokumentet

10.1093/annonc/mdy282.135

AUB Link

Søg efter materialet i Aalborg Universitetsbiblioteks søgemaskine

Citationsformater

Chen, I., Willumsen, N., Dehlendorff, C., Johansen, A., Vittrup, B. V., Krüger, M., Pfeiffer, P., Bjerregaard, J. K., Bojesen, S. E., Nielsen, S. E., Holländer, N. H., Yilmaz, M. K., Rasmussen, L. S., Karsdal, M., & Johansen, J. S. (2018). Clinical utility of serum type III collagen in patients with pancreatic carcinoma. Annals of Oncology, 29(Suppl. 8), viii257. Artikel 752P. https://doi.org/10.1093/annonc/mdy282.135

@article{190b9afab6b2464f97480a407f6fa004,

title = "Clinical utility of serum type III collagen in patients with pancreatic carcinoma",

abstract = "Background: Collagen is highly expressed in pancreatic cancer (PC) stroma. Collagen accumulation compromises penetration of macromolecules into tumor tissues and is associated with poorer outcome and increased tumor invasion. The aim of this biomarker study was to investigate the clinical utility of serum pro-peptide of type III collagen (PRO-C3) in patients (pts) with PC.Methods: A cohort from the Danish BIOPAC study (ClinicalTrials.gov ID: NCT03311776) including 851 consecutive subjects with histologically confirmed PC, ampullary carcinoma (n = 45), distal biliary tract cancer (n = 32) and benign lesions (n = 88) were enrolled. Serum PRO-C3 was determined by ELISA (Nordic Bioscience, PRO-C3 protocol). The main outcome was survival among pts with PC (male/female: 458/393; age \lt;50 vs. 50-69 vs. ≥70: 41/477/333; ECOG Performance Status (PS) of 0/1/2+: 315/340/110; stage 1 + 2/3/4: 234/142/456; diabetes yes/no: 207/629; smoking yes/no: 508/265; alcohol yes/no: 183/588; body mass index: low/normal/overweight: 62/426/254; Charlson Age-Comorbidity index (CACI) 0/1-2/3+: 34/296/504) in relation to PRO-C3 levels. Serum CA19-9, hyaluronic acid (HA), C-reactive protein (CRP), interleukin-6 (IL-6) and YKL-40 were measured. Hazard ratios (HRs) and 95\% confidence intervals (CIs) were estimated by Cox proportional hazards regression.",

author = "I Chen and N Willumsen and C Dehlendorff and A Johansen and Vittrup, {B V} and M Kr{\"u}ger and P Pfeiffer and Bjerregaard, {J K} and Bojesen, {S E} and Nielsen, {S E} and Holl{\"a}nder, {N H} and Yilmaz, {M K} and Rasmussen, {L S} and M Karsdal and Johansen, {J S}",

year = "2018",

month = oct,

doi = "10.1093/annonc/mdy282.135",

language = "English",

volume = "29",

pages = "viii257",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "Suppl. 8",

note = "ESMO 2018 Congress (European Society for Medical Oncology) ; Conference date: 19-10-2018 Through 23-10-2018",

url = "http://www.esmo.org/Conferences/ESMO-2018-Congress",

}

Chen, I, Willumsen, N, Dehlendorff, C, Johansen, A, Vittrup, BV, Krüger, M, Pfeiffer, P, Bjerregaard, JK, Bojesen, SE, Nielsen, SE, Holländer, NH, Yilmaz, MK, Rasmussen, LS, Karsdal, M & Johansen, JS 2018, 'Clinical utility of serum type III collagen in patients with pancreatic carcinoma', Annals of Oncology, bind 29, nr. Suppl. 8, 752P, s. viii257. https://doi.org/10.1093/annonc/mdy282.135

TY - ABST

T1 - Clinical utility of serum type III collagen in patients with pancreatic carcinoma

AU - Chen, I

AU - Willumsen, N

AU - Dehlendorff, C

AU - Johansen, A

AU - Vittrup, B V

AU - Krüger, M

AU - Pfeiffer, P

AU - Bjerregaard, J K

AU - Bojesen, S E

AU - Nielsen, S E

AU - Holländer, N H

AU - Yilmaz, M K

AU - Rasmussen, L S

AU - Karsdal, M

AU - Johansen, J S

PY - 2018/10

Y1 - 2018/10

N2 - Background: Collagen is highly expressed in pancreatic cancer (PC) stroma. Collagen accumulation compromises penetration of macromolecules into tumor tissues and is associated with poorer outcome and increased tumor invasion. The aim of this biomarker study was to investigate the clinical utility of serum pro-peptide of type III collagen (PRO-C3) in patients (pts) with PC.Methods: A cohort from the Danish BIOPAC study (ClinicalTrials.gov ID: NCT03311776) including 851 consecutive subjects with histologically confirmed PC, ampullary carcinoma (n = 45), distal biliary tract cancer (n = 32) and benign lesions (n = 88) were enrolled. Serum PRO-C3 was determined by ELISA (Nordic Bioscience, PRO-C3 protocol). The main outcome was survival among pts with PC (male/female: 458/393; age \lt;50 vs. 50-69 vs. ≥70: 41/477/333; ECOG Performance Status (PS) of 0/1/2+: 315/340/110; stage 1 + 2/3/4: 234/142/456; diabetes yes/no: 207/629; smoking yes/no: 508/265; alcohol yes/no: 183/588; body mass index: low/normal/overweight: 62/426/254; Charlson Age-Comorbidity index (CACI) 0/1-2/3+: 34/296/504) in relation to PRO-C3 levels. Serum CA19-9, hyaluronic acid (HA), C-reactive protein (CRP), interleukin-6 (IL-6) and YKL-40 were measured. Hazard ratios (HRs) and 95\% confidence intervals (CIs) were estimated by Cox proportional hazards regression.

AB - Background: Collagen is highly expressed in pancreatic cancer (PC) stroma. Collagen accumulation compromises penetration of macromolecules into tumor tissues and is associated with poorer outcome and increased tumor invasion. The aim of this biomarker study was to investigate the clinical utility of serum pro-peptide of type III collagen (PRO-C3) in patients (pts) with PC.Methods: A cohort from the Danish BIOPAC study (ClinicalTrials.gov ID: NCT03311776) including 851 consecutive subjects with histologically confirmed PC, ampullary carcinoma (n = 45), distal biliary tract cancer (n = 32) and benign lesions (n = 88) were enrolled. Serum PRO-C3 was determined by ELISA (Nordic Bioscience, PRO-C3 protocol). The main outcome was survival among pts with PC (male/female: 458/393; age \lt;50 vs. 50-69 vs. ≥70: 41/477/333; ECOG Performance Status (PS) of 0/1/2+: 315/340/110; stage 1 + 2/3/4: 234/142/456; diabetes yes/no: 207/629; smoking yes/no: 508/265; alcohol yes/no: 183/588; body mass index: low/normal/overweight: 62/426/254; Charlson Age-Comorbidity index (CACI) 0/1-2/3+: 34/296/504) in relation to PRO-C3 levels. Serum CA19-9, hyaluronic acid (HA), C-reactive protein (CRP), interleukin-6 (IL-6) and YKL-40 were measured. Hazard ratios (HRs) and 95\% confidence intervals (CIs) were estimated by Cox proportional hazards regression.

U2 - 10.1093/annonc/mdy282.135

DO - 10.1093/annonc/mdy282.135

M3 - Conference abstract in journal

SN - 0923-7534

VL - 29

SP - viii257

JO - Annals of Oncology

JF - Annals of Oncology

IS - Suppl. 8

M1 - 752P

T2 - ESMO 2018 Congress (European Society for Medical Oncology)

Y2 - 19 October 2018 through 23 October 2018

ER -